BioAlliance Pharma Launches Loramyc(R) In The UK, Germany And Denmark

Main Category: Cancer / Oncology
Also Included In: Infectious Diseases / Bacteria / Viruses
Article Date: 12 Jul 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

BioAlliance Pharma SA (Euronext Paris - BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the launch of its lead product Loramyc® on the British, German and Danish markets.

"This simultaneous product launch in three European countries crowns the efforts of our teams and marks another concrete step in the internationalization of our business. In these three countries, we are going to fully leverage our initial experience with the product in France", emphasized Dominique Costantini, BioAlliance Pharma's President and CEO. "In fact, prescriptions in France grew by 35% at the end of March (relative to the end of December 2007) and June's rate was 60% above the March figure. These progression rates confirm the product's market penetration and its appropriate response to a disease that affects severely ill patients. In France, over 8,000 patients have received a prescription of Loramyc® and our goal is to double that figure by the end of this year. The acceleration in prescription rates confirms the product's potential and will be the key element to observe in the UK, Germany and Denmark", added Dominique Costantini.

Loramyc® is now available in four European countries and will be commercialized in the UK, Germany and Denmark by SpeBio (a joint venture founded with SpePharm in order to sell the product throughout Europe). "The SpeBio team is committed to making the product available to private-practice and hospital-based oncologists, radiotherapists and infectious disease specialists", stated Jean-François Labbé (CEO of SpeBio). "The product has received a very warm welcome, since it fulfils an unmet medical need in the field of oropharyngeal candidiasis in immunocompromised patients".

With the UK, Germany and Denmark, BioAlliance Pharma is extending its European presence and, with SpeBio, is actively preparing market launches (that could take place before the end of this year) in additional European countries.

About BioAlliance Pharma

BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and in the USA with Par Pharmaceutical. In March 2008, BioAlliance Pharma signed a partnership agreement with Handok Pharmaceuticals for commercializing Loramyc® in Korea, Taiwan, Singapore and Malaysia and with Novamed Pharmaceuticals in June 2008 for commercialization of Loramyc? in China. In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD).

For more information, visit BioAlliance Pharma's website at http://www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).

BioAlliance Pharma's